Schering and Alliance complete deal
Schering and Alliance Pharmaceutical finalized their agreement last month regarding Imagent US, Alliance's ultrasound contrast agent, and provided additional details about the deal. The two companies will jointly develop the product, which will be
Schering and Alliance Pharmaceutical finalized their agreement last month regarding Imagent US, Alliance's ultrasound contrast agent, and provided additional details about the deal. The two companies will jointly develop the product, which will be marketed exclusively by Schering, of Berlin, Germany.
In exchange for the license, Schering will pay San Diego-based Alliance a $4 million licensing fee, plus additional payments predicated on the achievement of specified milestones and royalty payments based on worldwide sales. The payments could amount to $65 million if clinical trials, regulatory approvals, and market introductions result in a minimum amount of revenues. In addition, Schering's Schering Berlin Venture purchased $10 million in Alliance convertible preferred stock.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
